

S2 Table. Distribution of nodules with size change and *EGFR* mutation status for primary lung cancer^{a)}

	Positive for <i>EGFR</i> mutation (n=59)	Exon 19 del (n=26)	L858R (n=23)	Uncommon^{b)} (n=10)	Wild type <i>EGFR</i> (n=17)
Increase (size change $\geq +2$ mm)	0	0	0	0	2 (11.8)
No change (-2 mm < size change < $+2$ mm)	47 (79.7)	17 (65.4)	22 (95.7)	8 (80.0)	13 (76.5)
Decrease (size change ≤ -2 mm)	12 (20.3)	9 (34.6)	1 (4.3)	2 (20.0)	2 (11.8)

Values are presented as number (%). EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor. ^{a)}One patient, who received an EGFR-TKI without an *EGFR* mutation confirmation test and experienced the complete disappearance of the nodule, was not included in this analysis, ^{b)}Uncommon mutations were complex mutation exon 19, including p.E746_P753>VS, p.L747_A750>P, p.L747_T751>P, p.T751_I759>S, missense mutation in exon 20 (S768I) and missense mutation in exon 18 (G719X).